Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experience
Mitchell Sarkies(Macquarie University), Gerald F. Watts(Royal Perth Hospital), Nadarajah Kangaharan, Warrick Bishop, Jane Tiller(Monash Health), Jing Pang(The University of Western Australia), Philip E. Aylward(Flinders Medical Centre), Karam Kostner(Mater Health Services), Walter P. Abhayaratna(Australian National University), Ari Horton(Monash Children’s Hospital), Stephen J. Nicholls(Australian Centre for Heart Health), Karen Birkenhead(The University of Sydney), David Sullivan(Royal Prince Alfred Hospital), K. Waddell-Smith(Flinders Medical Centre), Jeffrey Braithwaite(Macquarie University), Shubha Srinivasan(Children's Hospital at Westmead), Andrew Black(Royal Hobart Hospital), Luke Elias, Jenny Della-Vedova(Government of Western Australia Department of Health), Charlotte Hespe
Cited by 6
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k